A Rigorous Monte Carlo Simulation Framework for Actinium-225-PSMA-617 Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer (EANM 2026) - Sep 29, 2026 - Abstract #EP-1012; "In conclusion, this study establishes MCNP6.3 and GATE as equivalent and reliable tools for 225Ac-PSMA-617 dosimetric analysis, with systematic differences well within clinically acceptable ranges. The demonstrated agreement across organ-level, microdosimetric, and radiobiological domains supports the continued development and clinical implementation of both platforms for targeted alpha therapy applications. These findings provide essential validation for regulatory submissions, clinical trial design, and treatment optimization protocols in the rapidly evolving field of targeted radionuclide therapy."
Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|